In yesterday’s Wall Street session, bluebird bio Inc. (NASDAQ:BLUE) shares traded at $3.35, up 0.60% from the previous session.
As of this writing, 14 analysts cover bluebird bio Inc. (NASDAQ:BLUE). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $11.00 and a low of $3.00, we find $7.50. Given the previous closing price of $3.33, this indicates a potential upside of 125.23 percent. BLUE stock price is now -7.06% away from the 50-day moving average and -29.47% away from the 200-day moving average. The market capitalization of the company currently stands at $356.21M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
There are 6 analysts who have given it a hold rating, whereas 3 have given it a buy rating. Brokers who have rated the stock have averaged $7.10 as their price target over the next twelve months.
With the price target of $4.21, HSBC Securities recently initiated with Buy rating for bluebird bio Inc. (NASDAQ: BLUE).
In other news, Klima Thomas J, insider sold 922 shares of the company’s stock on Sep 05. The stock was sold for $3,493 at an average price of $3.79. Upon completion of the transaction, the insider now directly owns 132,127 shares in the company, valued at $0.44 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 10, President and CEO Obenshain Andrew sold 16,929 shares of the business’s stock. A total of $59,956 was realized by selling the stock at an average price of $3.54. This leaves the insider owning 291,941 shares of the company worth $0.98 million. Insiders disposed of 36,402 shares of company stock worth roughly $0.12 million over the past 1 year. A total of 1.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BLUE stock. A new stake in bluebird bio Inc. shares was purchased by WALLEYE CAPITAL LLC during the first quarter worth $2,803,000. RENAISSANCE TECHNOLOGIES LLC invested $1,843,000 in shares of BLUE during the first quarter. In the first quarter, LION POINT CAPITAL, LP acquired a new stake in bluebird bio Inc. valued at approximately $1,780,000. CUBIST SYSTEMATIC STRATEGIES, LLC acquired a new stake in BLUE for approximately $1,251,000. HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND purchased a new stake in BLUE valued at around $1,183,000 in the second quarter. In total, there are 249 active investors with 81.30% ownership of the company’s stock.
Friday morning saw bluebird bio Inc. (NASDAQ: BLUE) opened at $3.3500. During the past 12 months, bluebird bio Inc. has had a low of $2.78 and a high of $8.58. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.10, and a quick ratio of 2.00. The fifty day moving average price for BLUE is $3.6062 and a two-hundred day moving average price translates $4.7300 for the stock.
The latest earnings results from bluebird bio Inc. (NASDAQ: BLUE) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.67, beating analysts’ expectations of -$0.72 by 0.05. This compares to -$1.36 EPS in the same period last year. The company reported revenue of $6.89 million for the quarter, compared to $1.52 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 353.59 percent. For the current quarter, analysts expect BLUE to generate $13.39M in revenue.
bluebird bio Inc.(BLUE) Company Profile
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company’s clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
